Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies

Abstract EN

Diabetes is a disease that can be treated with oral antidiabetic agents and/or insulin.

However, patients’ metabolic control is inadequate in a high percentage of them and a major cause of chronic diseases like diabetic retinopathy.

Approximately 15% of patients have some degree of diabetic retinopathy when diabetes is first diagnosed, and most will have developed this microvascular complication after 20 years.

Early diagnosis of the disease is the best tool to prevent or delay vision loss and reduce the involved costs.

However, diabetic retinopathy is an asymptomatic disease and its development to advanced stages reduces the effectiveness of treatments.

Today, the recommended treatment for severe nonproliferative and proliferative diabetic retinopathy is photocoagulation with an argon laser and intravitreal injections of anti-VEGF associated with, or not, focal laser for diabetic macular oedema.

The use of these therapeutic approaches is severely limited, such as uncomfortable administration for patients, long-term side effects, the costs they incur, and the therapeutic effectiveness of the employed management protocols.

Hence, diabetic retinopathy is the widespread diabetic eye disease and a leading cause of blindness in adults in developed countries.

The growing interest in using polyphenols, e.g., resveratrol, in treatments related to oxidative stress diseases has spread to diabetic retinopathy.

This review focuses on analysing the sources and effects of oxidative stress and inflammation on vascular alterations and diabetic retinopathy development.

Furthermore, current and antioxidant therapies, together with new molecular targets, are postulated for diabetic retinopathy treatment.